Triamterene (Teretam): Clinical Uses
Triamterene is a potassium-sparing diuretic primarily used to treat fluid retention (edema) in patients with heart failure, and to prevent or correct hypokalemia (low potassium) in patients taking other diuretics, particularly when combined with ACE inhibitors. 1, 2
Primary Indications
Heart Failure Management
Triamterene serves as an adjunctive diuretic in heart failure patients with the following specific roles:
- Prevention of diuretic-induced hypokalemia: Use triamterene only if hypokalemia persists after initiation of ACE inhibitors and loop or thiazide diuretics 1, 2, 3, 4
- Dosing: Initial dose 25-50 mg, usual daily dose 50-200 mg 3, 5, 3
- Monitoring protocol: Start with 1-week low-dose administration, check serum potassium and creatinine after 5-7 days, recheck every 5-7 days until potassium values stabilize 1, 2
Hypertension Treatment
In pediatric and adult populations:
- Pediatric dosing: Initial 1-2 mg/kg/day, maximum 3-4 mg/kg/day up to 300 mg/day, given twice daily 6
- Combination therapy: Often combined with thiazide diuretics (hydrochlorothiazide) to prevent potassium loss while maintaining antihypertensive effect 7
Critical Safety Considerations
Absolute Contraindications
- Do NOT combine with mineralocorticoid receptor antagonists (spironolactone, eplerenone) - risk of severe hyperkalemia 3, 5, 3
- Do NOT use with other potassium-sparing diuretics (amiloride) 3, 5, 3
- Avoid in patients with advanced renal impairment (GFR <30 mL/min) 1, 2
High-Risk Drug Interactions
Severe hyperkalemia risk when combined with:
- ACE inhibitors (captopril, enalapril, lisinopril)
- Angiotensin receptor blockers (losartan, valsartan)
- NSAIDs (increased risk of acute renal failure) 8
- Immunosuppressants (cyclosporine, tacrolimus) 9
Monitoring Requirements
When prescribing triamterene:
- Check serum potassium and creatinine after 5-7 days of initiation
- Recheck every 5-7 days until stable 1, 2, 4
- Monitor for signs of hyperkalemia (muscle weakness, cardiac arrhythmias)
- Watch for renal complications including nephrolithiasis and interstitial nephritis 8
Clinical Positioning
Triamterene is NOT a first-line diuretic. In heart failure management, the treatment hierarchy is:
- First-line: Loop diuretics (furosemide, bumetanide, torasemide) or thiazides with ACE inhibitors 1, 2, 10, 3
- Second-line for hypokalemia: Add triamterene only if hypokalemia persists despite ACE inhibitor therapy 1, 2, 4
- Severe heart failure: Consider spironolactone (aldosterone antagonist) before triamterene for mortality benefit 1, 2
Common Pitfalls to Avoid
- Never use triamterene as monotherapy for heart failure - always combine with ACE inhibitors and loop/thiazide diuretics 1, 2
- Avoid during ACE inhibitor initiation - wait until ACE inhibitor dose is stable to prevent hyperkalemia 1, 2
- Do not prescribe with over-the-counter NSAIDs - warn patients about ibuprofen, naproxen use due to acute renal failure risk 8
- Recent evidence suggests limited benefit in diuretic resistance - a 2023 trial showed no significant advantage of adding triamterene to hydrochlorothiazide in hospitalized HF patients with diuretic resistance 11
Emerging Research Applications
While not standard clinical indications, recent research has explored triamterene for:
- Glioblastoma treatment (CLIC1 inhibition) 12
- Overcoming cisplatin resistance in lung cancer (HDAC inhibition) 13
- Nonsense suppression therapy for genetic disorders 14
These remain investigational and are not approved clinical uses.